148 related articles for article (PubMed ID: 36509133)
1. Oral administration of CU06-1004 attenuates vascular permeability and stabilizes neovascularization in retinal vascular diseases.
Noh M; Kim Y; Zhang H; Kim H; Bae CR; Lee S; Kwon YG
Eur J Pharmacol; 2023 Jan; 939():175427. PubMed ID: 36509133
[TBL] [Abstract][Full Text] [Related]
2. Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin.
Smith RO; Ninchoji T; Gordon E; André H; Dejana E; Vestweber D; Kvanta A; Claesson-Welsh L
Elife; 2020 Apr; 9():. PubMed ID: 32312382
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathogenesis of retinal and choroidal vascular diseases.
Campochiaro PA
Prog Retin Eye Res; 2015 Nov; 49():67-81. PubMed ID: 26113211
[TBL] [Abstract][Full Text] [Related]
4. CD146 as a promising therapeutic target for retinal and choroidal neovascularization diseases.
Xue B; Wang P; Yu W; Feng J; Li J; Zhao R; Yang Z; Yan X; Duan H
Sci China Life Sci; 2022 Jun; 65(6):1157-1170. PubMed ID: 34729700
[TBL] [Abstract][Full Text] [Related]
5. [Aging and retinal vascular diseases].
Takagi H
Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):207-30; discussion 231. PubMed ID: 17402563
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
Aiello LP; Avery RL; Arrigg PG; Keyt BA; Jampel HD; Shah ST; Pasquale LR; Thieme H; Iwamoto MA; Park JE
N Engl J Med; 1994 Dec; 331(22):1480-7. PubMed ID: 7526212
[TBL] [Abstract][Full Text] [Related]
7. [Cell biology of intraocular vascular diseases].
Ishibashi T
Nippon Ganka Gakkai Zasshi; 1999 Dec; 103(12):923-47. PubMed ID: 10643294
[TBL] [Abstract][Full Text] [Related]
8. Epigalloccatechin-3-gallate inhibits ocular neovascularization and vascular permeability in human retinal pigment epithelial and human retinal microvascular endothelial cells via suppression of MMP-9 and VEGF activation.
Lee HS; Jun JH; Jung EH; Koo BA; Kim YS
Molecules; 2014 Aug; 19(8):12150-72. PubMed ID: 25123184
[TBL] [Abstract][Full Text] [Related]
9. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.
Saishin Y; Saishin Y; Takahashi K; Lima e Silva R; Hylton D; Rudge JS; Wiegand SJ; Campochiaro PA
J Cell Physiol; 2003 May; 195(2):241-8. PubMed ID: 12652651
[TBL] [Abstract][Full Text] [Related]
10. The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases.
Van Bergen T; Etienne I; Cunningham F; Moons L; Schlingemann RO; Feyen JHM; Stitt AW
Prog Retin Eye Res; 2019 Mar; 69():116-136. PubMed ID: 30385175
[TBL] [Abstract][Full Text] [Related]
11. Imidazole-based alkaloid derivative LCB54-0009 suppresses ocular angiogenesis and lymphangiogenesis in models of experimental retinopathy and corneal neovascularization.
Kim BH; Lee J; Choi JS; Park DY; Song HY; Park TK; Cho CH; Ye SK; Joo CK; Koh GY; Kim TY
Br J Pharmacol; 2015 Aug; 172(15):3875-89. PubMed ID: 25917462
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases.
Pe'er J; Shweiki D; Itin A; Hemo I; Gnessin H; Keshet E
Lab Invest; 1995 Jun; 72(6):638-45. PubMed ID: 7540233
[TBL] [Abstract][Full Text] [Related]
13. Α-Melanocyte-Stimulating Hormone Protects Early Diabetic Retina from Blood-Retinal Barrier Breakdown and Vascular Leakage via MC4R.
Cai S; Yang Q; Hou M; Han Q; Zhang H; Wang J; Qi C; Bo Q; Ru Y; Yang W; Gu Z; Wei R; Cao Y; Li X; Zhang Y
Cell Physiol Biochem; 2018; 45(2):505-522. PubMed ID: 29402864
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor-A
Ved N; Hulse RP; Bestall SM; Donaldson LF; Bainbridge JW; Bates DO
Clin Sci (Lond); 2017 Jun; 131(12):1225-1243. PubMed ID: 28341661
[TBL] [Abstract][Full Text] [Related]
15. Co-inhibition of PGF and VEGF blocks their expression in mononuclear phagocytes and limits neovascularization and leakage in the murine retina.
Balser C; Wolf A; Herb M; Langmann T
J Neuroinflammation; 2019 Feb; 16(1):26. PubMed ID: 30732627
[TBL] [Abstract][Full Text] [Related]
16. SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy.
Nguyen H; Chen H; Vuppalapaty M; Whisler E; Logas KR; Sampathkumar P; Fletcher RB; Sura A; Suen N; Gupta S; Lopez T; Ye J; Tu S; Bolaki M; Yeh WC; Li Y; Lee SJ
Transl Vis Sci Technol; 2022 Sep; 11(9):19. PubMed ID: 36149648
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy.
Zhang X; Bao S; Hambly BD; Gillies MC
Int J Biochem Cell Biol; 2009 Dec; 41(12):2368-71. PubMed ID: 19646547
[TBL] [Abstract][Full Text] [Related]
18. Dietary Compound Chrysin Inhibits Retinal Neovascularization with Abnormal Capillaries in db/db Mice.
Kang MK; Park SH; Kim YH; Lee EJ; Antika LD; Kim DY; Choi YJ; Kang YH
Nutrients; 2016 Dec; 8(12):. PubMed ID: 27918469
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress.
Caldwell RB; Bartoli M; Behzadian MA; El-Remessy AE; Al-Shabrawey M; Platt DH; Liou GI; Caldwell RW
Curr Drug Targets; 2005 Jun; 6(4):511-24. PubMed ID: 16026270
[TBL] [Abstract][Full Text] [Related]
20. The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders.
Hu TT; Vanhove M; Porcu M; Van Hove I; Van Bergen T; Jonckx B; Barbeaux P; Vermassen E; Feyen JHM
Exp Eye Res; 2019 Mar; 180():43-52. PubMed ID: 30472075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
